A strain producing 5-methylpyrazine 2-carboxylic acid and its construction method and application

By expressing ice nucleoprotein fusion aldehyde dehydrogenase in Escherichia coli, the catalytic efficiency of 5-methylpyrazine-2-carboxylic acid is improved, and the problem of low catalytic efficiency of biological enzymes is solved, achieving more efficient and environmentally friendly production method.

CN118703414BActive Publication Date: 2024-11-19TIANJIN IND MICROORGANISM TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411210736.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-19
Estimated Expiration
2044-08-30

AI Technical Summary

Technical Problem

The current biological enzyme method has low catalytic efficiency for producing 5-methylpyrazine-2-carboxylic acid, which limits its industrial application. The chemical synthesis method has harsh conditions, low selectivity and yield, resulting in a large amount of three wastes.

Method used

Using ice nucleoprotein (inaK) as a carrier protein, the aldehyde dehydrogenase is fused in E. coli, and the expression method is optimized, and the surface display efficiency of the enzyme is improved, forming inaK containing deleting some sequences. A fusion protein of the source protein xylC, used for whole-cell catalytic synthesis of 5-methylpyrazine-2-carboxylic acid.

Benefits of technology

It significantly improves the efficiency of whole-cell catalysis, improves the production efficiency and selectivity of 5-methylpyrazine-2-carboxylic acid, reduces the cost of enzyme preparation, and simplifies the purification and recycling process of enzymes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118703414B_ABST
    Figure CN118703414B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biotechnology, and discloses a strain producing 5-methylpyrazine-2-carboxylic acid, a construction method thereof and an application thereof. The present invention adopts ice nucleation protein inaK as a carrier protein, and fusion-expresses an aldehyde dehydrogenase that can be used to synthesize 5-methylpyrazine-2-carboxylic acid in Escherichia coli. The present invention uses Escherichia coli with a clear genetic background and rapid growth as an expression plate bacterium, and achieves the best effect by constructing different fusion modes and optimizing the plasmids of different expression vectors. That is, by adopting a surface display method to fix and express the target enzyme on the cell surface, the efficiency of whole-cell catalysis is significantly improved compared with a control without surface display, and has great practical value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology and discloses a strain for producing 5-methylpyrazine-2-carboxylic acid and a construction method and application thereof. Background Art

[0002] 5-Methylpyrazine-2-carboxylic acid is a drug intermediate and a key intermediate raw material for synthesizing the lipid-lowering drug acipimox and the blood sugar-lowering drug glipizide. The main preparation methods include chemical synthesis, electrochemical synthesis and bio-enzyme methods. The industrialized preparation method is mainly based on chemical synthesis, but strong oxidants such as hydrogen peroxide and potassium permanganate are usually used, the reaction conditions are harsh, difficult to control, low yield, low reaction selectivity, and a large amount of three wastes are generated. The bio-enzyme method has the advantages of mild reaction conditions, high reaction selectivity and yield, but there are still problems such as low catalytic efficiency of crude enzyme living cells, which limits its further application. A method for enzymatic production of 5-methylpyrazine-2-carboxylic acid is disclosed in Chinese patent CN201710645354.5, which expresses an aldehyde dehydrogenase and realizes the enzyme-catalyzed synthesis of 5-methylpyrazine-2-carboxylic acid, but industrial applications require the use of cheaper crude enzymes or cells for catalysis to reduce the preparation cost of the enzyme.

[0003] Cell surface display technology refers to the expression of exogenous proteins (also known as passenger proteins) by fusion of carrier proteins. The carrier proteins can bind to the cell outer membrane to carry the exogenous proteins to the cell surface. On the one hand, it overcomes the difficulty of substrate and enzyme protein being unable to contact due to the barrier of the cell membrane and improves the reaction efficiency of substrate and enzyme. On the other hand, cell surface display greatly simplifies the process and cost of enzyme protein purification and recycling. Three construction methods of display vectors: N-terminal fusion, C-terminal fusion, sandwich fusion (see Figure 1 ).

[0004] Ice nucleation protein (INP) is a secreted exogenous protein that can stably express exogenous proteins and has successfully achieved surface display of other exogenous proteins with larger molecular weight. Studies have shown that Pseudomonas syringae ( Pseudomomas syringae ) has a high expression stability. Summary of the invention

[0005] The present invention uses ice nucleation protein inaK as a carrier protein to express aldehyde dehydrogenase that can be used to synthesize 5-methylpyrazine-2-carboxylic acid in Escherichia coli. Escherichia coli with a clear genetic background and rapid growth is used as the expression base bacteria, and through the construction of different fusion methods and a series of optimizations of plasmids of different expression vectors, it is finally determined that the expression of pYB1s-inaKNC-xylC recombinant plasmid in Escherichia coli BL21 (DE3) base bacteria is the best, thus completing the present invention.

[0006] The invention provides a strain for producing 5-methylpyrazine-2-carboxylic acid. The starting strain is Escherichia coli, into which an expression vector containing a gene encoding a fusion protein of an inaK protein with a partial sequence deleted and an exogenous protein xylC is introduced. The fusion protein comprises an inaK sequence, and its amino acid sequence is shown in SEQ ID NO: 4 (the nucleotide sequence encoded by the inaK sequence is obtained by deleting nucleotides in the interval of 586-3297 from the full-length sequence of the inaK sequence, and connecting 1-585 and 3298-3453), and the C-terminus is fused with the N-terminus of the exogenous protein xylC.

[0007] Preferably, the expression vector is a pET28a vector, the encoding gene is placed behind a T7 promoter and inserted between NdeI and XhoI multiple cloning sites.

[0008] Specifically, the starting strain was Escherichia coli BL21(DE3).

[0009] The present invention also provides a method for constructing the strain, characterized in that an expression vector containing a gene encoding a fusion protein of the inaK protein with a partially deleted sequence and the exogenous protein xylC is introduced into the starting strain, and the strain producing 5-methylpyrazine-2-carboxylic acid is verified and determined.

[0010] The present invention further provides application of the strain in preparing 5-methylpyrazine-2-carboxylic acid.

[0011] Specifically, the strain is used as a whole-cell catalyst.

[0012] The present invention also provides a method for preparing 5-methylpyrazine 2-carboxylic acid, which comprises culturing the strain to obtain a whole-cell catalyst, and using 5-methyl-2-pyrazinaldehyde to form a reaction system to prepare 5-methylpyrazine 2-carboxylic acid.

[0013] In a specific embodiment, the strain is fermented in LB culture medium, and arabinose or IPTG is used as an inducer; the fermented bacterial liquid is centrifuged to collect wet bacterial cells for reaction.

[0014] Preferably, the reaction system is as follows: 5-methyl-2-pyrazinaldehyde 15-25 mM, pH 7.5 Tris-HCl 40-60 mM, wet bacteria 5-15 mg / mL. The reaction temperature is 28-32°C, and the reaction is shaken at 150-250 rpm. More preferably, the reaction system is as follows: 5-methyl-2-pyrazinaldehyde 20 mM, pH 7.5 Tris-HCl 50 mM, wet bacteria 10 mg / mL; the reaction temperature is 30°C, and the reaction is shaken at 200 rpm.

[0015] The present invention studies and screens the best method, and uses surface display to fix and express the target enzyme on the cell surface, thereby significantly improving the efficiency of whole-cell catalysis compared with the control without surface display. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 These are three ways of fusion of passenger protein and carrier protein.

[0017] Figure 2 This is the plasmid map of the inaK tool.

[0018] Figure 3 This is the plasmid map No. 1.

[0019] Figure 4 This is the plasmid map No. 2.

[0020] Figure 5 This is the plasmid map of No. 4.

[0021] Figure 6 This is the map of plasmid No. 5.

[0022] Figure 7 This is the map of plasmid No. 6.

[0023] Figure 8 This is the reaction process curve of 500mL system. DETAILED DESCRIPTION

[0024] 1. Comparison of the expression effects of the full-length ice nuclease protein as a carrier protein and after deleting some of the repetitive sequences. The main features of plasmids 1 to 5 constructed in the subsequent examples are:

[0025] Plasmid 1: The xylC gene fragment was inserted between the NdeI and XhoI multiple cloning sites of the pET28a vector;

[0026] Plasmid No. 2 pET28a-inaK-xylC: The full-length inaK sequence (1-3453 bp, the nucleotide sequence is shown in SEQ ID NO: 1, and the encoded amino acid sequence is shown in SEQ ID NO: 3) was introduced behind the T7 promoter of the pET28a vector, and the C-terminus of the full-length inaK sequence was fused with the N-terminus of the exogenous protein xylC;

[0027] The nucleotide sequence of the exogenous protein xylC used in the example is shown in SEQ ID NO: 5, and the encoded amino acid sequence is shown in SEQ ID NO: 6;

[0028] Plasmid No. 3 pET28a-inaKNC-xylC: A fusion protein coding sequence is introduced behind the T7 promoter of the pET28a vector. The fusion protein is a truncated inaK protein inaKNC (i.e., an inaK protein with a partial sequence deleted, and its amino acid sequence is shown in SEQ ID NO: 4), the C-terminus of which is fused to the N-terminus of the exogenous protein xylC and inserted between the NdeI and XhoI multiple cloning sites;

[0029] Plasmid No. 4 introduces the full-length inaK sequence (1-3453bp) behind the pBAD promoter in the pBAD-inaK-xylC plasmid, and the C-terminus of the full-length inaK sequence is fused with the N-terminus of the exogenous protein xylC.

[0030] Plasmid No. 5 is in the pBAD-inaKNC-xylC plasmid. An inaK sequence with a partial sequence deleted is introduced behind the pBAD vector promoter (after deleting the nucleotides in the range of 586-3297, 1-585 and 3298-3453 are connected, and the nucleotide sequence is shown in SEQ ID NO: 2), and the C-terminus is fused with the N-terminus of the exogenous protein xylC.

[0031] 2. The relevant sequences used in the embodiment are as follows:

[0032] SEQ ID NO: 1 (DNA sequence of inaK):

[0033]

[0034] SEQ ID NO: 2 (DNA sequence of inaKNC):

[0035] atgaccctggataaagcactggttctgcgtacctgtgccaataatatggcagatcattgtggtctgatttggcctgcaagcggcaccgttgaaagccgttattggcagagcacccgtcgtcatgaaaatggtctggttggtctgctgtggggtgcaggcaccagcgcatttctgagcgttcatgcagatgcacgttggattgtttgtgaagttgcagttgcagatattatcagcctggaagaacctggtatggttaaatttccgcgtgccgaagttgttcatgttggtgatcgtattagcgcaagccattttatcagcgcacgtcaggcagatccggcaagcaccagcacctcaaccagcaccagtacactgaccccgatgccgaccgcaattccgacaccgatgcctgcagttgccagcgttaccctgccggttgcagaacaggcacgtcatgaagtttttgatgttgcaagcgttagcgcagcagcagctccggttaatacactgccggttaccacaccgcagaatctgcagaccgcaacctatggtagcaccctgagcggtgataatcattcacgtctgatttttcgtctgtgggatggtaaacgttatcgtcagctggttgcacgtacaggtgaaaatggcgttgaagccgatattccgtattatgtgaatgaggatgatgacatcgttgataaaccggatgaagatgatgattggatcgaggtgaaactcgagtga。

[0036] SEQ ID NO: 3 (Full-length amino acid of inaK):

[0037]

[0038] SEQ ID NO: 4 (inaK NC amino acid sequence):

[0039] MTLDKALVLRTCANNMADHCGLIWPASGTVESRYWQSTRRHENGLVGLLWGAGTSAFLSVHADARWIVCEVAVADIISLEEPGMVKFPRAEVVHVGDRISASHFISARQADPASTSTSTSTSTLTPMPTAIPTPMPAVASVTLPVAEQARHEVFDVASVSAAAAPVNTLPVTTPQNLQTATYGSTLSGDNHSRLIFRLWDGKRYRQLVARTGENGVEADIPYYVNEDDDIVDKPDEDDDWIEVKLE*.

[0040] SEQ ID NO: 5 (nucleotide sequence of xylC):

[0041]

[0042] SEQ ID NO: 6 (amino acid sequence of xylC):

[0043] MRETKEQPIWYGKVFSSNWVEARGGVANVVDPSNGDILGITGVANGEDVDAAVNAAKRAQKEWAAIPFSERAAIVRKAAEKLKEREYEFADWNVRECGAIRPKGLWEAGIAYEQMHQAAGLA SLPNGTLFPSAVPGRMNLCQRVPVGVVGVIAPWNFPLFLAMRSVAPALALGNAVILKPDLQTAVTGGALIAEIFSDAGMPDGVLHVLPGGADVGESMVANSGINMISFTGSTQVGRLIGEKC GRMLKKVALELGGNNVHIVLPDADLEGAVSCAAWGTFLHQGQVCMAAGRHLVHRDVAQQYAEKLALRAKNLVVGDPNSDQVHLGPLINEKQVVRVHALVESAQRAGAQVLAGGTYQDRYYQA TVIMDVKPEMEVFKSEIFGPVAPITVFDSIEEAIELANCSEYGLAASIHTRALATGLDIAKRLNTGMVHINDQPINCEPHVPFGMGASGSGGRFGGPASIEEFTQSQWISMVEKPANYPF*.

[0044] Example 1: Plasmid construction

[0045] 1. Tool plasmid pET28a-inaK:

[0046] This plasmid was synthesized by General Biotech and inserted into the plasmid pET28a (Wuhan Miaoling Biotechnology Co., Ltd., Cat. No. P0024) between XhoI and NdeI. The plasmid map is shown in Figure 2 The DNA sequence of inaK is shown in SEQ ID NO: 1.

[0047] 2. Plasmid No. 1 pET28a-xylC: This plasmid was synthesized by General Biotech and xylC was inserted between XhoI and NdeI of plasmid pET28a (Wuhan Miaoling Biotechnology Co., Ltd., Cat. No. P0024). See the plasmid map for details. Figure 3The DNA sequence of xylC is shown in SEQ ID NO: 2 (see Chinese patent application CN201710645354.5), and the protein encoded by it can catalyze the conversion of 5-methylpyrazinaldehyde into 5-methylpyrazinoic acid. The present invention optimizes and upgrades its expression and strain construction methods, and fixes the corresponding aldehyde dehydrogenase encoded by xylC to the cell surface by fusing surface display proteins, significantly improving its catalytic efficiency and application effect.

[0048] 3. Plasmid No. 2 pET28a-inaK-xylC:

[0049] The plasmid map is shown in Figure 4 The build process is as follows:

[0050] Small fragment amplification and purification: Construction of plasmid. Using the tool plasmid pET28a-xylC as a template, the gene xylC was amplified using primers ET-xylC-F / ET-xylC-R. The PCR system and PCR conditions are shown in Table 1. The size was about 1460 bp. The nucleic acid gel fragments were purified using the gel recovery kit (Omega Bio-Tek, Inc, USA, catalog number D2500-02) according to the instructions to obtain small gene fragments.

[0051] Amplification and purification of vector fragments: Using pET28a-inaK as a template, use ET-inaK-F / ET-inaK-R primers to amplify the vector fragment with the homology arm of the gene inaK. The PCR system and PCR conditions are shown in the table below. Use the gel recovery kit (Omega Bio-Tek, Inc, USA, product number D2500-02) to purify the nucleic acid gel fragments to obtain the vector gene fragment.

[0052] Gene fragment and vector fragment ligation: The aforementioned inserted gene fragment and vector fragment were ligated using the Hieff ligase kit (New England Biolabs (NEB) Company, Catalog No. R0176). 10 µL of the ligation product was added to the E. coli TOP10 competent cells (Tiangen Biochemical Technology (Beijing) Co., Ltd., Catalog No. CB104-02), placed on ice, gently mixed and placed on ice for 30 min. Then, the centrifuge tube was placed in a preheated 42 ℃ constant temperature water bath, heat-shocked for 90s, and the centrifuge tube was immediately placed on ice for 2 min. 1 mL of LB liquid culture medium was added and cultured at 37 ℃ and 220 r / min shaking for 1 h. After recovery, the centrifuge was placed in a centrifuge at 6000 rpm for 2 min, most of the supernatant was discarded, and the cell pellet and the remaining supernatant were mixed by pipetting with a pipette tip, spread on the LB solid plate, and cultured inverted overnight at 37 ℃ or 30 ℃ incubator. A single colony was picked and inoculated into an LB liquid test tube and cultured at 37°C, 200 rpm for 12 h. The bacteria were collected by centrifugation (4000 rpm, 2 min). The target plasmid was extracted according to the instructions of the plasmid extraction kit (Tiangen Biochemical Technology (Beijing) Co., Ltd., Cat. No. DP105-03) and stored at -20°C for future use.

[0053] Table 1 PrimeSTAR Mix polymerase PCR amplification system

[0054]

[0055] PCR reaction program: pre-denaturation at 98 °C for 2 min, then the following cycle: denaturation at 98 °C for 10 s, annealing at 55 °C for 20 s, extension at 72 °C at 3K bp / min, 30 cycles; extension at 72 °C for 2 min, cooling to 4 °C for storage.

[0056] 4. Plasmid No. 3 pET28a-inaKNC-xylC, Plasmid No. 4 pBAD-inaK-xylC, Plasmid No. 5 pBAD-inaKNC-xylC:

[0057] Plasmids 3, 4, and 5 were constructed according to the corresponding primers and templates shown in Table 2 (the plasmid maps are shown in Figure 5 , Figure 6 , Figure 7 ), the experimental operation is the same as the aforementioned plasmid No. 2 construction process.

[0058] Table 2 Primer table (including construction plasmid number, corresponding primers, template)

[0059]

[0060] Example 2: Construction of bacterial strains

[0061] 1. Construction of bacteria 01, bacteria 02, and bacteria 03: Take out the competent cells of Escherichia coli BL21 (DE3) (Tiangen Biochemical Technology (Beijing) Co., Ltd., catalog number CB105-02) from the -80 ℃ refrigerator, place them on ice, and add 1 µL of plasmids 1, 2, and 3 respectively in the clean bench. Mix gently and place on ice for 30 min. Then place the centrifuge tube in a preheated 42 ℃ constant temperature water bath, heat shock for 90 s, immediately put the centrifuge tube on ice for 2 min, add 1 mL LB liquid culture medium, and culture at 37 ℃, 220r / min shaking for 1 h. After recovery, put it in a centrifuge at 6000 rpm, centrifuge for 2 min, discard most of the supernatant, use a pipette tip to blow and mix the cell pellet and the remaining supernatant, spread it on the LB solid plate containing the corresponding antibiotics, and culture it inverted overnight in a 37 ℃ or 30 ℃ incubator.

[0062] 2. Construction of bacteria 04 and 05: Take out the competent cells of Escherichia coli BW25113 (Beijing Zhuangmeng International Biogene Technology Co., Ltd., catalog number ZC1027-2) from the -80 ℃ refrigerator, place them on ice, and add 1µL of plasmids 4 and 5 respectively in the clean bench. Mix gently and place on ice for 30 min. Then place the centrifuge tube in a preheated 42 ℃ constant temperature water bath, heat shock for 90 s, immediately put the centrifuge tube on ice for 2 min, add 1 mL of LB liquid culture medium, and culture at 37 ℃, 220 r / min shaking for 1 h. After recovery, put it in a centrifuge at 6000 rpm, centrifuge for 2 min, discard most of the supernatant, use a pipette to blow and mix the cell pellet and the remaining supernatant, spread it on the LB solid plate containing the corresponding antibiotics, and culture it inverted overnight in a 37 ℃ or 30 ℃ incubator.

[0063] Example 3: Strain culture, bacterial cell collection and whole-cell catalytic activity test

[0064] 1. Strain culture and bacterial cell collection: Take the above-constructed strains and coat them on LB solid agar plates, culture them at 37°C overnight, pick a single clone from the plate and place it in a LB liquid test tube at 37°C, 200rpm for 6-8 hours, transfer to a 1L shake flask, fill it with 200ml LB medium, add the corresponding inducer arabinose or IPTG when OD600 reaches 0.8, culture at 30°C overnight, and measure OD600. Take the fermentation broth in the above example and collect the bacterial cells by centrifugation (4000rpm, 10 minutes)

[0065] 2. Whole-cell catalytic reaction conditions: The reaction system was configured according to the table below. The reaction solution was placed in a 1.5 mL centrifuge tube and placed in a shaker at 30 ° C and 200 rpm for shaking reaction. Samples were taken after 5 hours and the product content was detected by liquid chromatography. Detection method: Shimadzu liquid chromatography LC2030; C18 column (4.6*250 mm); 20% pure acetonitrile and 80% trifluoroacetic acid aqueous solution (0.1% volume percentage) were used as mobile phases, flow rate 1 mL / min, injection volume 5 μL, detection wavelength 275 nm. Bacteria 01 is aldehyde dehydrogenase xylC without ice nucleation protein fusion. Bacteria 02, bacteria 03, bacteria 04, and bacteria 05 are strains constructed by using ice nucleation protein through different fusion methods and expression vectors. The application effect of whole-cell catalysis can be clearly seen. The conversion rate and efficiency of strains after fusion expression are significantly improved compared with strains without ice nucleation protein fusion. Among them, the fusion method and expression vector of bacteria 3 are the best combination of application effect. The results are shown in Tables 3 and 4 below.

[0066] Table 3 Whole cell reaction system

[0067]

[0068] Table 4 Product content and conversion rate results

[0069]

[0070] 3. Bioreactor scale-up reaction conditions: Take the fermentation broth of bacteria 03 in the above embodiment, collect the bacteria by centrifugation (4000rpm, 10 minutes) for later use. Weigh 4.88 g of 5-methyl-2-pyrazinaldehyde, dissolve it in 500mL of water, add it to a 2 L bioreactor (Bai Lun Bio-fermentation Tank-BLBIO-2GJ-2), stir and dissolve it fully, adjust the pH to 7.5 with 1M sodium hydroxide aqueous solution, keep it at 30°C, add 5 g of the wet bacteria collected above, stir and start the reaction, and take samples at 1, 2, 3, 4, 6, and 8 hours respectively to detect the product content by liquid chromatography. Detection method: Shimadzu liquid chromatography LC2030; C18 column (4.6*250mm); use 20% pure acetonitrile and 80% trifluoroacetic acid aqueous solution (0.1% volume percentage) as the mobile phase, flow rate 1mL / min, injection volume 5μL, detection wavelength 275nm. The optimal bacteria 03 screened by the small reaction system was verified in a larger reaction volume of 500ml and at a higher concentration level, and achieved good application results. After 8 hours of reaction, the product concentration reached 39.2Mm and the conversion rate reached 98% (the results are shown in Figure 8 as shown).

Claims

1. A strain for producing 5-methylpyrazine-2-carboxylic acid, wherein the starting strain is Escherichia coli, characterized in that: An expression vector containing a gene encoding a fusion protein of the inaK protein with a partial sequence deleted and the exogenous protein xylC is introduced, wherein the amino acid sequence of the inaK protein with a partial sequence deleted is as shown in SEQ ID NO: 4, and its C-terminus is fused with the N-terminus of the exogenous protein xylC; The expression vector starting vector is pET28a vector.

2. The strain according to claim 1, characterized in that The coding gene was placed behind the T7 promoter on the pET28a vector and inserted between the NdeI and XhoI multiple cloning sites.

3. The strain according to claim 1, characterized in that The starting strain was Escherichia coli BL21(DE3).

4. The method for constructing a strain according to any one of claims 1 to 3, characterized in that: The expression vector containing the coding gene of the fusion protein of the inaK protein with a partial sequence deleted and the exogenous protein xylC is introduced into the starting strain, and the strain producing 5-methylpyrazine 2-carboxylic acid is verified and determined.

5. Use of the strain according to any one of claims 1 to 3 in the preparation of 5-methylpyrazine-2-carboxylic acid.

6. The use according to claim 5, characterized in that The strain was used as a whole-cell catalyst.

7. A method for preparing 5-methylpyrazine dicarboxylic acid, characterized in that: The whole cell catalyst is obtained by culturing the strain as claimed in any one of claims 1 to 3, and 5-methyl-2-pyrazinaldehyde is used to form a reaction system to prepare 5-methylpyrazine 2-carboxylic acid.

8. The method according to claim 7, characterized in that The strain is fermented in LB culture medium with IPTG as an inducer; the fermented bacterial liquid is centrifuged to collect wet bacterial cells for reaction.

9. The method according to claim 8, characterized in that The reaction system is as follows: 5-methyl-2-pyrazinaldehyde 15-25 mM, pH 7.5 Tris-HCl 40-60 mM, wet bacteria 5-15 mg / mL; The reaction temperature was 28-32°C and the reaction was shaken at 150-250 rpm.

10. The method according to claim 9, characterized in that The reaction system was as follows: 5-methyl-2-pyrazinaldehyde 20 mM, pH 7.5 Tris-HCl 50 mM, wet bacteria 10 mg / mL; The reaction temperature was 30°C and the reaction was shaken at 200 rpm.